Congratulation to Prabtibh Sharma, Vinay K Puduvalli and team demonstrating the anti-glioma effects of NAMPT inhibition in vitro and on ex vivo slice cultures! MD Anderson Cancer Center

congratultions Amy Heimberger, MD!

Pleased to share our comprehensive review on Neurologic Toxicities of Immunotherapy! #Neurology #Immunotherapy #EndCancer MD Anderson Cancer Center

“Apart from hope’s fundamental role in healing,giving hope is one of the most beautiful acts of kindness.True,there is always the danger that the hope given may be unrealistic.But just as a bit of light dissipates alot of darkness,so can a bit of hope ameliorate a lot of despair”

Congratulations! Hussein Tawbi, MD, PhD and team! MD Anderson Cancer Center Treatment advances in melanoma inspire all oncologists! #EndCancer

Our updated Immunotherapy for Neuro-Oncology chapter is now available online! MD Anderson Cancer Center Soecial thanks to John de Groot, MD, Pushan Dasgupta, Aung Naing, Joud Hajjar MD, PhD, MS: pubmed.ncbi.nlm.nih.gov/34972967/

Agree! This is a great resource for our patients! #BrainTumor #PatientCare

Congratulations! Your proud sister and mentee! ❤️Reza Majdzadeh

Enjoyed reading this article by my amazing colleague and friend, ⁦Ashley Aaroe, MD. Our field is lucky to have you as our patients’ advocate! #neurology, #braintumor, ⁦⁦MD Anderson Cancer Center⁩ neurologylive.com/view/neurology…

To help reduce your cancer risk, aim for at least 150 minutes of moderate activity each week. Watch to see ideas for getting active. #HealthAndWellness #EndCancer

Two of my favorite leaders committed to #endcancer! You are our source of inspiration! W. K. Alfred Yung MD , MD Anderson Cancer Center

The just-announced U.S. Supreme Court decision in Dobbs v. Jackson Women’s Health Organization represents a stunning reversal of precedent that inserts government into the personal lives and health care of Americans. nej.md/3Aa5cKe

Great honor to see Dr. Tanner and Dr. Yung W. K. Alfred Yung MD at #ASCO23!

It was my honor and a privilege to present the highlights of CNS tumors at #ASCO2023! Specially, highlighting the historical study by Dr. Mellinghoff and colleagues. nejm.org/doi/full/10.10…. Thank you ASCO organizers! MD Anderson Cancer Center

Our newly activated trial is specifically designed for patients with oligodendroglioma (CIC mutated) and NF1-associated gliomas clinicaltrials.gov/ct2/show/NCT05…. Excited to announce this unique trial and accrue patients! #endcancer, MD Anderson Cancer Center

DDR 🤴!!! The Taylor Swift of Oncology!!! The man the myth……………Tim Yap!! MD Anderson Cancer Center #ASCO24

congratulations! very well deserved!

Do you have a newly diagnosed GBM, MGMT unmethylated patient who would benefit from more resection? We have a clinical trial opportunity for them. mdanderson.org/patients-famil… #endcancer MD Anderson Cancer Center

Do you have a newly diagnosed GBM patient, MGMT unmethylated with KIT or PDGFRA alterations? Phase 2 trial of avapritinib at MDA would provide an opportunity for upfront targeted therapy after chemoRT. Please reach out if you have trial candidates. MD Anderson Cancer Center Stacie Walker

Exciting trial for patients with low grade gliomas! - We are targeting ERK for treatment of recurrent oligodendroglioma and NF1-associated low-grade glioma using ulixertinib in our surgical trial clinicaltrials.gov/study/NCT05804…. MD Anderson Cancer Center #endcancer